It’s all happening at Biotech Showcase™ Week

December 21, 2016 Guest Contributor

Guest post by Constantine Theodoropulos, President, GO Therapeutics

Thankfully there is a holiday between now and Biotech Showcase™ Week in San Francisco (Jan 9–11), because we are going to need to rest up for what promises to be a one of the most dynamic and productive life sciences industry gatherings of the year.

The triple play events of Biotech Showcase, Medtech Showcase and Digital Medicine Showcase is expected to attract 3,500 industry executives from hundreds of companies across the most significant segments of the healthcare industry. While JP Morgan Healthcare conference gets its fair share of the fanfare for hosting many of the largest companies in the industry, Biotech Showcase Week’s line up of events is where tomorrow’s leaders can be found and accessed. Speaking from experience, personal ambition is the only limitation on meeting with the companies, executives and investors who can potentially make a profound positive impact on your future.

At Biotech Showcase Week, whatever your interest there is an opportunity to match it. Here is small sampling of what’s on offer:

  • Immuno-Oncology remains hot. Since my company (GO Therapeutics) plays in this sandbox, I am interested in getting a progress report on the latest development in the field. So I’ll be sure to pay close attention to the panel “The overflowing IO buffet: Next-gen IO antibodies, oncolytic viruses, bispecifics, adoptive cell therapies and oral immunometabolism/immuno-epigenetic agents” on Wednesday, January 11, 2017 (11 am–12 pm).
  • Since I like to invest in biotech, I’ll be paying close attention at the “Small-cap watch list 2017” panel Wednesday,  January 11, 2017 (8–9 am) where senior healthcare analysts discuss their top small-cap biotech picks.
  • There is no mistaking technology’s sweeping impact on healthcare, so who can afford to miss Digital Medicine Showcase?  There is no better way to see how technology is impacting the R&D processes, strengthening the patient-physician relationship, and simultaneously enabling individuals to become the CEO of their own health than at the “State of the Digital Medicine Industry” panel on Tuesday,  January, 10, 2017 (8–8:55 am).
  • I’ve always made it a point to attend the Alliance for Regenerative Medicine (ARM) presentation track, to learn about the pioneering companies and science in this field. Take for example ViaCyte, who is developing islet cell replacement therapy for insulin-requiring diabetes. Or Helios, which is a leader in iPS cells which can be differentiated into various organ-specific cells or tissues (retina, liver, heart, kidney, etc.).
  • With more than 390 companies presenting at Biotech Showcase Week, there is a likely match to your interests, no matter how specialized. For example, in women’s health, a company called NeRRe Therapeutics is developing its unique tachykinin portfolio: NT-814 a dual mechanism neurokinin (NK)-1, 3 antagonist for Women’s health-related diseases and orvepitant and the NK-1 antagonist pipeline for conditions related to neuronal hypersensitivity. How about in-silico discovery using matching learning? Recursion Pharmaceuticals combines innovative biological science with machine learning and deep learning to discover new therapeutic opportunities with a focus on rare genetic diseases.  How about the microbiome? Track down Rebiotix, a clinical stage biotechnology company that is developing drugs to treat debilitating diseases using the human microbiome.
  • Finally, as the intensity of the week winds down, I’ll be at the all-star reporters’ panel to hear their unique take on the news, trends and issues that will reverberate in 2017, and beyond. These top biotech reporters will surely have a fresh take on the top newsmakers and analysis of the week’s biggest stories heard around Union Square.

As you can see, it’s all happening at Biotech Showcase Week in San Francisco.




Previous Article
Investors’ appetite for the life sciences continued in 2016
Investors’ appetite for the life sciences continued in 2016

Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence While 2015 was a record ...

Next Article
Lifetime trends in biopharmaceutical innovation: Recent evidence and implications
Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life...